GIS vs RLMD · P/E 8.2, rev $4.61B vs $692.3M cap
General Mills Inc (GIS) versus Relmada Therapeutics Inc (RLMD) — a side-by-side from cached financials, not a winner call.
General Mills Inc (GIS) is a packaged foods company listed on NYSE.
Relmada Therapeutics Inc (RLMD) is a biotechnology company listed on NASDAQ.
Latest reported GIS revenue for 2026-05-31 was $4.61B. Net income was -$2.01B. Revenue was up 1.2% from 2025-05-25 to 2026-05-31. GIS currently screens at market cap $17.80B and trailing P/E 8.2.
RLMD does not have a complete income-statement cache yet.
GIS currently screens at market cap $17.80B and trailing P/E 8.2. RLMD currently screens at market cap $692.3M.
Not investment advice. Open the GIS and RLMD stock pages for the full models.
Not investment advice.